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Abstract: C-C chemoattractant cytokine (chemokine) receptor 6 (CCR6) and its exclusive binding
molecule CCL20 is an extremely important chemokine receptor-ligand pair which controls cell
migration and immune induction during inflammatory disease. Not many scientific studies have
been undertaken to study its immune mechanisms in detail, but its unique contribution to steady
state cell chemotaxis in upholding immune tolerance and regulating immune homeostasis during
inflammation is evident in multiple systems in the human body, including skin, liver, lung, kidney,
brain, eye, joints, gonads and the gut. The role of CCR6 is constitutively expressed as a series
of much debilitating severe inflammatory and autoimmune diseases, Human Immunodeficiency
Virus (HIV) and cancer metastasis. CD4+ T cells, the central organizers of adaptive immunity,
are stringently mobilized by the CCR6/CCL20 axis also induced by cytokines and a host of other
factors in a carefully executed immune modulation scenario, to bring about a delicate balance
between inflammation inducing TH17 cells and regulatory Treg cells. Although the exact immune
regulatory role is not elucidated as yet, the CCR6/CCL20 axis is implicated as a front runner which
determines the polarization of TH17 and regulatory Treg cells, upon which depends the resolution or
progression of many debilitating disorders. This review therefore aims at emphasizing the pleiotropic
significance of the chemokines CCR6 and CCL20 in immunologic function in multiple organ systems,
thereby hoping to accentuate its value in future therapeutic modalities.
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1. Introduction
Chemokines
Chemokines represent an exclusive cell directing system in the body, consisting of signaling
proteins vital to the immune system. The primary role of chemokines in infections is to attract immune
cells bearing their cognate receptors to sites of inflammation. The best example is corroborated
by the role of chemokines in mucosal immunity, where epithelial cells of the mucosa activated by
an inflammatory stimulus releases the chemokine ligands, constitutively inducing chemotaxis of
the leukocytes bearing their corresponding receptors towards them [1]. This is necessarily how
chemokines mediate immune modulation and maintain cell migration during immune homeostasis or
inflammation. Chemokines have also been described by other names, such as a specific ‘cell positioning’
system [2] or a potential ‘cell navigating’ system [1] which brings about immune modulation in multiple
organ systems of the human body.
The chemokine repertoire described so far includes 50 different chemokines and 20 different
receptors. Chemokine receptors are externally displayed on the surface of a range of cells [2] such as T
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and B lymphocytes, macrophages, dendritic cells, peripheral blood mononuclear cells, innate lymphoid
cells, neuron, epithelial and endothelial cells [3].
Chemokines, abbreviated from ‘chemoattractant cytokines’, mediate their biological effects
across G-protein coupled receptors [1]. These surface–bound receptors are specifically borne by
a wide range of immune and non-immune cells. Biochemically, chemokine receptors function as
guanine nucleotide exchange factors, mainly limited to the pertussis–toxin sensitive G1 class of G
proteins. Their immunological effects consist of coordinating leucocyte development, differentiation,
distribution, chemotactic migration and their effector capabilities [4]. The biological impact of
chemokines produces multiple outcomes: (i) embryonic development; (ii) angiogenesis; (iii) T-helper
subset development; (iv) leukocyte homeostasis; (v) wound healing; (vi) lymph organogenesis;
(vii) inflammatory disorders; (viii) tumor proliferation and metastasis; and (ix) B cell maturation
and antigen-induced B cell differentiation [1,4–8].
Chemokines consist of small proteins having a molecular weight of 8 to 14 kilo Dalton [9].
The structure reveals three beta pleated sheets with an alpha helix at the carbon terminal and
disulfide bonds connecting cysteine subunits. Chemokines are said to be composed of secreted,
structurally related proteins having 67–127 amino acids. The functional form is highlighted as
a monomer, although they could exist as either a monomer, dimer or tetramer [1]. Chemokines
are named based on their receptors and each sub class, CC, CXC, CX3C or XC is identified by the
number and spacing of preserved cysteines. R denotes receptor and it is followed by a number
which lists out the chronological order of discovery [9]. Thus “CC chemokines have CCR chemokine
receptors” to bind with. Some chemokines bind specifically to one receptor such as the cognate
receptor, CCR6 and its exclusive ligand, CCL20. Chemokines can ligate with more than one receptor
or several chemokine receptors can attach to more than one chemokine, among which the CCR6 and
its ligand CCL20 forms an exclusive monogamous pair [1]. Chemokines are known to actively recruit
immature or effector cells to affected sites during maintenance of immune tolerance or promoting
inflammation, but interestingly inhibition of chemokines have shown to develop anti-inflammatory
properties, encouraging the exploration of novel therapeutic breakthroughs in medical treatment [10].
Chemokine-aided T cell chemotaxis is directly linked to a number of immune-activated diseases.
Leukocyte migration from blood to tissue is a multi-step process. It involves selectin-mediated
rolling on endothelium and chemoattractant-mediated integrin activation, followed by leukocyte
extravasation and chemotaxis up a chemoattractant gradient [4]. Upon synthesis within the cell,
chemokines are secreted and get tethered to glycosaminoglycans, a group of sulfated polysaccharides
present in the extracellular matrix or surface which constructs a steady chemokine gradient that
ensures binding with its receptor [1].
2. Chemokine Receptor CCR6 and Its Ligand CCL20
CCR6 in Homo sapiens is identified by many synonymous codes: DCR2, DRY6, BN-1, CCR-6,
CMKBR6, GPRCY4, STRL22, CD196, CKRL3, GPR29, CKR-L3, CC-CKR-6 or C-C CKR-6 [11].
CCL20 was identified as the sole known ligand to bind with CCR6 using CCL20 induced mobilization
of calcium in K562 cells devoid of other receptors (CCR1-5) except CCR6 [1]. Five other chemokines
(CCL2-5 and 17) did not bind to CCR6, although there is documented research stating CCL18 as
a possible binding partner [12]. When CCL20 binds to CCR6, the receptor becomes internalized
with its expression reduced on the cell surface [1]. Beta-defensins, a group of anti-bacterial peptides,
have been shown to elicit chemotaxis through CCR6 although its activity on CCR6 still remains
experimental [13].
CCL20, discovered using bioinformatics techniques is known by several names such as,
macrophage inflammatory protein (MIP3α), Exodus-1 and liver and activation regulated chemokine
(LARC). Th17 cells are known to express CCL20 but it is not expressed by the regulatory T cells or
other T helper subsets [1]. CCL20 expression is markedly up regulated in the intestinal epithelial
cells only as a response to intrusive or non-intrusive bacteria possessing flagella, and is labelled as
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an inflammation-inducing chemokine [14]. Cells linked to inflammation such as endothelial cells,
neutrophils, Th17 cells, B cells, natural killer (NK) cells, dendritic cells, macrophages and Langerhans
cells, reportedly express CCL20 [15].
CCR6 is naturally expressed in multiple tissues: maximally in the appendix, spleen, lymph nodes
and pancreas and minimally in the thymus, colon, small intestine, fetal liver and testis [11]. CCR6 is
upregulated by numerous leukocyte cohorts, such as B-cells, T-cells (specifically pro-inflammatory
TH17 cells and immune regulatory Treg cells), immature dendritic cells, NKT cells, innate lymphoid
cell 3 and neutrophils [16].
The dominant role of CCR6 in inflammatory disease is underpinned by its influence on driving the
T helper subset differentiation and maintaining leukocyte homeostasis. Naïve T helper cells resident
in lymph nodes, upon antigen sampling will differentiate into its effector sub populations, TH17 and
regulatory Treg cells, TH1 and TH2, mediated by the prevailing cytokine environment and a host of
other factors. However a critical factor which determines the development of TH17 and Treg subsets
evidently becomes the upregulation of CCR6 as both these cell sub types are known to be CCR6+ CD4+
T cells. Thus proliferation, migration and promoting pro-or anti -inflammatory effects of these helper
sets might be primarily CCR6 dependent processes [17].
CD4+ T helper cells are the most important key players in organizing adaptive immunity.
Naïve CD4+ CD45 RB high T cell populations, when activated by antigen presenting cells, differentiate into
the mainstream TH1 and TH2 classical lineages. They regulate cellular immunity through their
respective signature cytokine profiles, namely, IFN-γ, TNF-α and IL-1β in TH1 and IL-4, IL-5 and Il-13
in TH2. TH1 is pro-inflammatory by nature while TH2 mediates humoral and allergic responses [18].
TH1 and TH2 differ in immune function as well as migratory capability by expressing distinct
chemokine e receptors which modulate selective recruitment into sites of inflammation. The other two
T helper subsets, TH17 and regulatory T cells (Tregs), specifically express CCR6 but not always by the
TH1 or TH2 cells [19].
Research from different groups have conferred opposing roles to TH17 and regulatory Treg cells
in inflammatory disease [1]. IL-23 induced TH17 differentiation is known to promote inflammation
and intriguingly TH17 also release CCL20, the chemokine ligand of CCR6. With either an autocrine
or paracrine secretion of CCL20, TH 17 cells also trigger a self-perpetuating cycle at inflammatory
locations in a positive feedback loop. IL-17 production also induces TNF-α and IL-1β, pointing towards
an inflammatory pathway involving the nuclear transcription factor NF-kB [20]. FoxP3+ bearing
regulatory Treg cells are primarily disease suppressive in function and promote disease resolution by
downregulating inflammatory T cell proliferation and is inducible through TGF-β and IL-10 [21].
CCR6 expression on TH17 cells is induced through the cytokines, TGF-β, IL-6, IL-17, IL-21 and
IL-23 as well as lineage- distinct, principal transcription factors RORγt and RORα [4]. CCL20 can be
induced in a number of cell types by lipopolysaccharide (LPS) and also stimulated and up-regulated
by the inflammatory cytokines IL-1α and TNFα during acute inflammation. CCL20 expression is
constitutively up-regulated by other inflammation- inducing cytokines, namely, IFN-γ IL-1β, IL-17,
IL-21 [22]. In contrast, IL-10, which is anti-inflammatory, dampens CCL20 expression indicating
that this chemokine does not very well favor the accumulation of regulatory T cells particularly at
inflammatory locations. IL-4, IL-22 and surprisingly, IL-23 have reported insignificant stimulatory
effects on CCL20 expression [4].
CCR6 confers an antagonistic function in these T helper populations, the TH17 and Treg cells,
although it is unknown what other factors are responsible for tipping the balance in favor of disease
progression. CCR6-CCL20 axis remains the pivotal point which determines reciprocal generation
of these two cell types but simultaneously highlights the importance of CCR6 in T cell migration.
A disrupted CCR6-CCL20 axis only leads to the development of inflammation because CCR6
is adequately expressed on regulatory T cell populations in the cure phenotypes. A study involving
the transfer of “wild type” TH17 cells and CCR6 deficient T cells into a “Rag1−/− severe combined
immune deficient (SCID) mice” resulted in extreme intestinal inflammation and a subsequent reduction
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in TH17 and Treg populations occurring [1]. CCR6 expression is deemed to be critical to Treg cells than
to TH17 cells, because this subset suppresses inflammatory T cell proliferation and promotes disease
resolution. Research documented so far has assigned dual roles to CCR6 in inflammation and immune
homeostasis [23].
3. CCR6 Signaling Pathway
CCR6 on leukocytes having bound to CCL20 initiates a signal transduction cascade via
activation of the Gαi subfamily of heterotrimeric G proteins. Synonymous with most of the classical
chemokine receptors, the downstream signaling of CCR6 initiates activation of calcium mobilization,
phospholipase, and phosphatidylinositol 3-kinase, followed by ERK1/2 phosphorylation and actin
polymerization [24].
Cell responses to chemokines include natural sensitivity to pertussis toxin, which is an indication
that the G1 class proteins are annexed to the signaling pathway downstream of the receptor.
As explained by Figure 1, activated G protein, subsequent to releasing guanosine di phosphate (GDP)
and binding with guanosine tri phosphate (GTP), dissociates into Gβγ and Gα subunits. Gβγ then
activates membrane-amalgamated phospholipase C-β2 (PLC) and phosphoinositide 3-kinase (PI3K).
PI3K catalyzes phosphatidylinositol 4, 5 bi-phosphate (PIP2) into phosphatidylinositol 4, 5 bi-phosphate
3 (PIP3) which is next converted into inositol triphosphate (IP3). Concomitantly diacylglycerol (DAG)
is activated by PLC. IP3 regulates the mobilization of calcium ions from intracellular depots and DAG
acts in resonance with calcium to activate different isoforms of protein kinase C (PKC). Turned on PKC
and various Ca—innervated protein kinases catalyze phosphorylation, thereby activating successive
signaling episodes which end up in cell migration [4].
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Figure 1. Schematic represen ation of C-C chemoattractant cytokin (chemokin ) receptor 6 (CCR6)
activation pathway. After binding with the ligand, G Protein Coupled Receptors (GPCR) are activated
to release the Gβ and Gγ subunits which in turn activate PLC and PI3 kinase. PI3 kinase then
converts PIP2 to PIP3 which activates calcium ion mobilization across IP3. IP3 with DAG stimulated
by calcium ion activate PKC and other PKCs which trigger ph sphorylation c u ing cell migration.
Legend for abbreviations: Gα, Gβ, Gγ—Subunits of GPCR, PI3 kinase—Phosphoinositide 3 kinase,
PLC—Phospholipase Cβ2, DAG—diacylglycerol, PIP2—Phosphatidylinositol 4,5-bisphosphates,
PIP3—Phosphatidylinositol 4,5-bisphosphates 3, IP3—Inositol triphosphate, PKC—Protein kinase
C, ER—endoplasmic reticulum, Ca+2—Calcium ions. Reproduced from [4]. Copyright 2003, CRC Press:
Boca Raton, FL, USA.
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4. CCR6 and CCL20 in Health and Disease
CCR6 and CCL20 have been implicated as potential manipulators which create a significant
impact on human health and disease. In normal health, this pair performs an immune tolerance role
by up-regulating immune suppression. When confronted with an inflammatory stimulus FoxP3+
regulatory Treg cells tend to proliferate aided by its cytokine milieu [25]. If this typical homeostatic
function is disrupted, it is known to bring forth a marked increase of the TH1/TH17 axis thereby
promoting adverse immunologic function of multiple systems culminating in a number of diseases,
namely, sarcoidosis, idiopathic pulmonary fibrosis, chronic liver disease, experimental autoimmune
encephalomyelitis, multiple sclerosis, rheumatoid arthritis, dry eye disease, psoriasis, glomerular
nephritis, inflammatory bowel disease, HIV and an array of malignant cancers and their metastasis as
shown by both Table 1 and Figure 2.
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Figure 2. Schematic represe tation of the immunological impact of CCR6/CCL20 axis on multiple
organs in the human body and the cells involved in promoting disease given next to each organ. EAE,
IPF lungs, Chronic liver disease, DED, Rheumatoid arthriti , IBD, Psoriasis, Glomerular nephritis,
HIV and Cancer metastasis are all diseases driven by the CCR6-CCL20 axis and disease progression
leading to pathogenesis is promoted by T helper lymphocyte subsets, particularly TH17 and decrease
in Treg cells. The factors which tilt the TH17-Treg balance influenced by transcription factors
and cytokines in the tissue microenvironment is yet to be discovered. Legend for abbreviations:
EAE—Experimental Autoimmune Encephalomyelitis, IPF lungs—Idiopathic Pulmonary Fibrosis
lungs, DED—Dry Eye Disease, IBD—Inflammatory Bowel Disease, HIV—Human Immunodeficiency
Virus, APC—Antigen Presenting Cell, MHC Class II—Major Histocompatibility Complex Class
II, AM—Alveolar Macrophages, DC—Dendritic Cells, FB—Fibroblasts, AEC—Alveolar Epithelial
Cells, CCR6—Chemokine receptor 6, CCL20—Chemokine ligand 20, IL—Interleukin, TH1, TH2,
TH17, Treg—Regulatory Treg cells—T helper lymphocyte subsets, (γδ) T cells—gamma delta T
lymphocytes, NF-kB—nuclear factor kappa B, STAT3—signal transducer and activator of transcription
3. TNF-α—tumor necrosis factor-alpha.
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4.1. Lung
Adult human airways are not only a potential hub for harmful microbes, but are also exposed to
allergens, pollutants, pulmonary emboli, complement deposition or autoantibodies, because the lungs
are said to inhale around 10,000 L of air every 24 h. A typical response to these onslaughts by lung
injury is the localized synthesis and release of distinctive chemokines, which amplify the inflammatory
response. Inflammation is considered necessary in one way to defend, repair, protect against or subdue
an infection. Thus, activating leukocyte chemotaxis is vital to the development of antimicrobial host
defense [4].
Research from Facco et al. on pulmonary sarcoidosis had revealed CCR6 expression on TH1 cells.
CCR6 was co-expressed on alveolar macrophages in patients of sarcoidosis and alveolitis along with
CXCR3 and CXCR6. CCR6+ T cells infiltrated into the lung interstitial tissue and were responsive to
CCL20, CXCL10 and CXCL16. This observation amply demonstrates that T cells bearing CCR6 act in
a coordinated manner with ligand and inflammatory cytokines produced by TH1 during alveolitic
disease [25]. Further, CCR6 possesses the capability to recruit antigen-presenting immature and mature
dendritic cells (DC) and macrophages to sites of inflammation on the alveolar epithelium [26].
CCL18, released by alternatively activated macrophages, induced collagen synthesis by human
lung fibroblasts, indicating CCR6 as the receptor for CCL18, reported from a screened phage-display
library. Staining lung tissue indicated CCR6 presence on alveolar epithelial cells II (AEC-II) and
fibroblasts in idiopathic pulmonary fibrotic (IPF) lungs that blocks airways, but not in tumor-free areas
of squamous cell carcinoma patients. It inferred a role for CCR6-CCL18 involving fibroblasts in human
lung disease [12].
In contrast, gene delivery of human CCL18 to the lungs of wild type (WT) mice induced infiltration
of T lymphocytes to the lungs, but the expression of CCR6 was found to be below 5% in the lymphocyte
population. In the lungs of CCR6 knockout mice, CCL18-driven T lymphocyte trafficking was reduced
but not completely halted. These observations, made in vivo in mice, concluded that CCR6 was not
required for CCL18-induced changes, and that CCR6 is not the principal receptor for CCL18 in this
animal model [27].
4.2. Kidney
Glomerulonephritis is characterized by tissue damage caused due to T cell trafficking into the
kidney. Chemokines modulate the migration of T lymphocytes to sites of inflammation. Renal FoxP3+
regulatory T cells (Treg) and IL-17 releasing TH17 cells were shown to upregulate CCR6 while IFN-γ
releasing TH1 cells were CCR6 negative. Tregs and TH17 subsets displayed migratory capability
towards CCL20 which was markedly high in renal biopsies of experimental murine nephritis. T cell
recruitment was followed by pathogenesis in the kidney with albuminuria, leading to loss of renal
function [28]. Nephritic mice deficient in CCR6 demonstrated extreme renal damage and high mortality
in comparison to the wild type, due to less accumulation of Treg cells and TH17 cells and not that of
the TH1 type. This suggests an imbalance of Treg/TH17 paradigm associated with CCR6 mediation
exists in the kidneys too, similar to the gut. Reintroduction of WT Treg had offered protection to
CCR6 knockout mice against severe renal injury, confirming that CCR6 promotes the recruitment
of both TH17 and regulatory T reg cells to the kidney whereas a decrease in Tregs in the presence of TH1
response produced aggravated disease [29]. Tregs have been implicated in maintaining tolerance to
autoimmune renal disease, thereby lowering renal inflammation, and in preventing allogenic responses
in renal transplantation [30].
CCR6 and CCL20 are reportedly involved in recruiting T and B cells to kidney nodules during
chronic inflammation in individuals. The CCR6/CCL20 mRNA expression quantified in renal
biopsies of various nephropathies had revealed this cognate chemokine receptor was expressed
in a number of kidney-associated cells: CD20+ B cells, CD3+ T cells, tubular epithelial cells and the
peritubular and glomerular capillary endothelial cells although the functional role of CCR6 in the renal
endothelium had not been assessed. Similarly to CCR6-CCL20 acting as a mediator in the modelling
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of gut-associated lymphatic tissue, it is postulated that the nodular infiltrates in the kidney are also
formed in a CCR6-dependent manner [31].
4.3. Liver
Chronic liver injury results from hepatic inflammation, leading to organ fibrosis. Intrahepatic
increase in CCR6 and CCL20 expression was observed in patients with chronic liver disease compared
to healthy controls. It demonstrated that this chemokine receptor ligand pair may contribute to
the migration of gamma-delta (γδ) T cells, TH17 and regulatory (Treg) cells to sites of inflammation.
CCR6 was explicitly required by IL-17 expressing γδ T cells to gather in the injured liver and promote
disease resolution. Immunohistochemistry revealed accumulation of mononuclear cells bearing CCR6
induced by CCL20 secretion of hepatic parenchymal tissue in clinical liver disease. Compared to the
WT, CCR6 knockout mice developed more acute fibrosis with enhanced immune cell infiltration to the
liver [32,33].
4.4. Brain
TH17 is strongly associated with autoimmune diseases, as demonstrated by pre-clinical studies in
rheumatoid arthritis and multiple sclerosis. Neutralizing IL-17 as well as transfer of TH17 lacking CCR6
receptors had markedly inhibited experimental autoimmune encephalomyelitis (EAE). Apart from
autoimmune promoting, pro-inflammatory function of TH17 it is also known to bring about disease
resolution. Chemokines and adhesion molecules activate T cells, propelling them to migrate towards
the central nervous system (CNS). The choroid plexus constitutively express CCL20 and is thought
to act as an entry point for CCR6 expressing CD4+ T cells. EAE in animal models is used to study
multiple sclerosis, which is a demyelinating inflammatory disorder of the CNS and infiltrating T
cells contribute to its pathogenesis. Effector TH17 and TH1 subsets are found in multiple sclerosis
lesions along with the expression of cytokines IL-17 and IFN-γ. CCR6 demonstrates a critical aspect
in the entry of TH17 which is said to induce EAE in the CNS. CNS-infiltrating cells, when analyzed
directly for CCR6 expression, have revealed that in EAE, TH1 cells are in excess of TH17 CD4+ and
both subtypes however, expressed CCR6 [34,35].
Cerebral ischemia or stroke is ranked the second globally most common cause of death and is
a much-debilitating neurological disease condition. Immune-mediated tissue damage occurs in the
first few days of suffering a stroke and is mainly attributed to brain-infiltrating, IL-17 releasing, γδ T
cells which are largely positive for the chemokine receptor CCR6 as they trigger a highly conserved
immune reaction. In a model of experimental stroke, genetic deficiency in Ccr6 was associated with
diminished infiltration of natural IL-17 releasing γδ T cells and a significantly improved neurological
outcome, outlining the role CCR6 plays in pro-inflammatory immune cell chemotaxis to inflamed sites
in the brain [36].
4.5. Eye
TH17 cells are the principal effector cells causing inflammation in dry eye disease (DED),
an immune inflammatory condition affecting the ocular surface that can even lead to corneal
perforation. Local neutralization of CCL20 with antibodies administered sub-conjunctively to DED
mice had decreased TH17 cell permeation into the ocular surface producing improvement in clinical
signs, suggesting that CCR6 interaction with CCL20 could direct the passage of TH17 cells in the eye.
Inhibition of the CCR6/CCL20 axis is therefore projected as a novel therapeutic mechanism to treat
this condition [37].
4.6. Skin
The skin disorder atopic dermatitis (AD) is identified by a deficiency of keratinocytes in the skin,
which produces less CCL20, and similarly such patients also display a reduction in the expression
of CCR6, which leaves them exposed to viral infections leading to eczema herpeticum (ADEH) or
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eczema vaccinatum (EV). A population-based study of European and African descent had recorded
single nucleotide polymorphism (SNP) in CCL20 in native Europeans significantly associated with
AD, suggesting that variants in CCL20 and CCR6 are highly relevant to AD and increase the risk of
severe viral complications in this skin disease [38].
Psoriasis is a commonly occurring autoimmune skin disease that involves TH17 associated
signaling pathways. CCR6 deficient mice had failed to develop psoriasiform dermatitis in skin
following IL-23 injections, because IL-23 is a growth and differentiation factor of TH17 cells and
hence a typical driver of TH17 mediated inflammation, validated by previous research showing
that recombinant IL-23 injections given to mice skin results in psoriasiform dermatitis that mimics
human psoriasis in as short a period as 5 days. A more recent experimental model has documented
that dermal CCR6+ TH17 cells are sustained by IL-23 released from dendritic cells and these TH17
populations release IL-22 to stimulate epidermal hyperplasia through signal transducer and activator
of transcription 3 (STAT3) mediated mechanisms in the human skin. Additionally, positive feedback
was provided by epidermal and dermal production of CCL20, potentially recruiting more CCR6
expressing T cells or antigen presenting cells into inflamed psoriatic skin. Inhibition of CCR6 has been
suggested to provide a possible therapeutic pathway to cure this disease [39,40].
4.7. Joints
Rheumatoid arthritis causes chronic inflammation of the joints where chemokines regulate
infiltration of synovial fluid by inflammatory cells. This autoimmune disease is characterized
by the increased release of CCL20 and the buildup of CCR6 bearing mononuclear T cells in the
joints. An arthritis-induced study model of CCR6−/− mice had not exhibited any clinical signs
consistent with disease compared to WT controls, but revealed that CD4+ T cells, TH17 cells and
CD25 FoxP3+ regulatory T cells showed up-regulation of CCR6 with RANKL, which contributed
towards disease, particularly osteoclastogenesis. A possible role in pathogenesis is thus highlighted in
CCR6 in promoting inflammation at the joints [41–43]. Ccr6 single nucleotide polymorphisms (SNPs)
have demonstrated diminished basal and ligand induced Gαi protein signaling which predisposes
individuals to diseases such as rheumatoid arthritis [44].
4.8. Gonad
Capacitated human sperm is said to exhibit a directional movement towards CCL20 having the
CCR6 receptor localized in the tail and a recent study revealed modifications in motility parameters of
spermatozoa in the presence of chemokines. In non-inflammatory conditions, chemokine receptor/
ligand interactions within the reproductive tracts of the both sexes are known to promote sperm
motility and chemotaxis. Physiological reactions are thus mediated by CCR6 ligands in the male
genitourinary system which extends beyond an inflammatory response, and this observation underpins
its significance in clinical reproduction and also possibly in contraception [45].
4.9. Gut
Animal models of the past and present have identified: (i) genetic predisposition; (ii) the
composition of associated microbiome; (iii) breakdown of innate immune barriers—disruption of
the mucosal barrier due to decreased mucin synthesis, dysfunctional Toll-like and Nod-like receptor
mediated pathways leading to increased pathogenicity, endoplasmic reticulum (ER) stress mediated
apoptosis; (iv) deregulated adaptive immunity; and (v) a plethora of environmental factors, as multiple
causes responsible for inflammatory disorders in the gastrointestinal tract (GI) and disruption of the
CCR6/CCL20 axis, also as a significant contributing factor [46–49].
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Table 1. Organ systems and the diseases in which CCR6/CCL20 axis is operative along with the cell
types involved in the disease progression which express CCR6.
Organ CCR6/CCL20 Axis Cell Types Involved Disease Produced References
Lung Operative Fibroblasts, AEC, DC, TH1, AM IPFL, Sarcoidosis [12,25,26]
Liver Operative TH17, Treg, (γδ) T cells Chronic liver disease [32,33]
Kidney Operative TH1, TH17, Treg Glomerular nephritis [28–31]
Brain Operative TH1, TH17, (γδ) T cells EAE, Stroke [34–36]
Eye Operative TH17 Dry eye disease [37]
Skin Operative TH17 Psoriasis [39,40]
Joints Operative CD25-FoxP3+ Rheumatoid arthritis [41–43]
Gut Operative TH17, Treg, TH1 IBD [1,50–52]
GWAS have confirmed Ccr6 as a risk allele of GI tract infections, among the 200 or so susceptibility
loci already identified. It confirms that infectious diseases of the gut exhibit gene dependency and also
gives prominence to the CCR6/CCL20 axis as a potential risk factor which determines disease outcome.
TH17 cells are directed to the small intestine by CCR6 upon immune induction and not only TH17,
but also FoxP3+ regulatory Tregs are upregulated, given the fact that CCR6 performs dual functions
with regards to these two helper T subsets in gut associated lymphoid tissue (GALT). Accumulation
of TH17 cells in the spleen and bone marrow in CCR6 deficient mice showed they were unable to
migrate due to the absence of this receptor, and hence produced less intestinal inflammation. This fact
further supports its role in directing immune cell movement in the gut and confirms that TH17 plays a
pro-inflammatory role in intestinal disorders [50–52].
Intestinal microbiome which comprises of around 100 trillion cells is important for: (i) colonization
and maintenance of immune cells; (ii) TH17—Treg balance in the gut; and (iii) protection against
intestinal pathogens, evidenced by a reduction in TH17 and elevated Treg populations in mice given:
(i) antibiotics; and (ii) bred in germ-free conditions. The disease outcome therefore primarily depends
upon the CCR6-CCL20 axis, with microbiota featuring as another additional contributor [53,54].
Inflammatory bowel disease (IBD), which is an autoimmune GI tract disorder, consists of two
clinical variants, Crohn’s disease and Ulcerative colitis. A Ccr6 knockout murine models had displayed:
(i) smaller Peyer’s patches; (ii) reduced sub epithelial domes; (iii) absence of isolated lymphoid follicles;
(iv) reduced intestinal M cell numbers; (v) increased resistance to bacteria which enters through M
cell conduits; (vi) marked elevation in the number of TH17 cells in the spleen and lymph nodes;
(vii) Reduced migration to inflamed sites and less suppressive capabilities of Treg cells; (viii) moderate
and severe disease in DSS and TNBS induced colitis respectively; and (ix) transfer of naïve T cells to
Rag2−/− mice resulting in aggravated disease [55–57]. SNPs in Ccr6 have been reported to predispose
individuals to Crohn’s disease [44].
4.10. Cancer
Chemokines are utilized by cancer cells to directly invade the lymphatic system and spread
via blood, as well as determine the location of metastatic growth of various tumors. CCL20 has
been reportedly expressed in varied human cancer types, such as melanoma, adenocarcinoma,
hepatocellular carcinoma leukemia, lymphoma, prostate cancer, colorectal, oral and lung squamous cell
carcinoma and pancreatic carcinoma (PCA) [58,59]. The CCL20/CCR6 system has been demonstrated
within pancreatic cancer cell lines and PCA-associated tissues. The stimulation of PCA cells
expressing CCR6 with CCL20 had constitutively triggered cell proliferation, tendency to migrate
and invasion of tissues indicating that CCL20 could act using mechanisms of autocrine and paracrine
secretion. Recent studies have identified matrix metalloproteinase production to up-regulate CCL20,
which promotes pancreatic tumor cell movement and their metastatic invasion [58].
A new interesting theme that involves chemokine receptor function is that chemokine receptors
are equipped to drive cancer metastasis. Similar to CCR7 being useful for the movement of T
cells within lymph nodes, when chemokine receptors are expressed in tumor cells, they may direct
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organ-targeted tumor metastasis. Precise signals which exist on the tumor cell surface, along with
the establishment of chemotactic gradients, will allow them to migrate to metastatic destinations
of numerous cancers. Various chemokine ligands have been strongly identified in directing metastasis
into lymph nodes [59–61].
The chemokine superfamily is said to provide a useful target to find new important drugs because
G protein coupled receptors (GPCR) are ideal for testing small molecular inhibitors, and therefore many
best-selling anti-cancer therapeutics in the market today have targeted GPCR [62,63]. CCR6 inhibition
in patients undergoing surgical treatment or clinical therapy has been proposed to be important
to prevent liver metastasis of cancer, by a study of BALB/c mice. They showed overexpression of
functional CCR6 and CCR7 on metastatic tumor cell lines obtained from the liver. Cell migration was
studied employing green fluorescent protein-labelled metastatic cells and CCR6 mRNA was measured
by RT-PCR. Results displayed preferential colonization of liver-sorted tumor cells when pre-incubated
with the CCR6 ligand, which is constitutively expressed by hepatocytes. This demonstrates that
CCR6 directs and drives the mechanisms of chemotaxis, commonly adopted by malignant cancers
when metastasizing to the liver [33]. Mutations in Ccr6 also have been associated with a case of
mucosa-associated lymphoid tissue (MALT) lymphoma [64].
4.11. HIV
Preferential infection by HIV of CCR6+ TH17 cells in vitro has been described in a study which
had cultured both TH1 and TH17 cells obtained from peripheral blood of healthy individuals in the
presence of activated IL-1β and IL-23. IL-23 was added to promote the expansion of TH17 cells.
Infection by HIV had produced negligible effects on TH1 whilst causing a significant reduction in
TH17 cells, increased infection of TH 17 cells and cell death. It reportedly demonstrated a possible
role for CCR6 in the internalizing of the virus within T helper populations [65]. In a more recent
observation in relation to HIV infection of TH17 cells, CCR6 was presented as a weak alternative
sub-receptor alongside the receptors CXCR4 and CCR5, which may provide an entry route to HIV
invading the T helper cell subsets. This fact suggests that preferential infection of T cells takes place
without CCR6 mediation. Yet, the importance of the CCR6/CCL20 axis is by no way diminished in
HIV pathogenesis because this receptor- ligand pair is deemed to be actively recruiting TH17 cells
and DCs to infection sites, thus helping the virus to propagate to other locations of the body [66].
Envelope surface glycoprotein gp120 is known to significantly promote the CCR6 expression on human
B cells [11].
4.12. Obesity and Diabetes
The CCR6-CCL20 alliance is said to promote inflammation, leading to pathophysiological
malignancies such as obesity and diabetes. Minor inflammation of the adipose tissue has been linked
with obesity and is tactically driven via the CCR6-CCL20 axis. Adipose tissue lymphocytes expressing
CCR6 have demonstrated chemotactic migration towards mature adipocytes which upregulate the
chemokine ligand CCL20. Strongly enhanced CCL20 expression by adipocytes displayed a positive
correlation with the body mass index (BMI), in visceral adipose tissue compared to the subcutaneous
fat layers [67].
Increased leukocyte streaming into pancreatic islets causes inflammation in the beta cell mass
influencing apoptosis and dysfunction. A study by Burke et al. had identified elevation of CCL20 levels
in pancreatic beta cells induced by the transcriptional factor nuclear factor kappa B (NF-kB). They
suggested intervening at the NF-kB –mediated chemokine upregulation, to disrupt the CCR6-CCL20
axis, which could become a therapeutic mechanism to negate inflammation-triggered dysfunction
seen in both obese and diabetic individuals. T cell immunity is suppressed by the activation of type
III histone deacetylase Sirtuin 1, which is known to regulate cellular processes via the SIRT1 gene.
Resveratrol is a Sirtuin-1 activator which demonstrated therapeutic efficacy in a Nucleotide-binding
and oligomerization domain (NOD) mouse model of type 1 diabetes. Resveratrol-treated mice
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exhibited a significant decrease in Ccr6 in a gene array analysis, correlating with decreased migration in
CCR6+ macrophages and IL-17 producing cells into the pancreas from pancreatic lymph nodes [68,69].
5. Conclusions
The CCR6/CCL20 axis thus demonstrates a vital role in determining the disease outcome of
inflammatory disorders and cancer metastasis in multiple organ systems in the human body. Inhibition
of the CCR6/CCL20 axis is expected to open up new vistas for discovering novel therapeutics in the
treatment of human disorders, and a variety of therapeutic antibodies have already been made against
the chemokine receptor 6. Effective blocking of the CCR6 signal transduction pathway using novel
biochemical interventions might prove to be a useful therapeutic strategy in regulating pro-disease
inducing cell chemotaxis within inflammatory microenvironments. Most of the research has been
centered on animal models which do not depict the true clinical picture, therefore there remains an
urgent need for the evaluation of this chemokine receptor 6 and its ligand pair in expanded in vivo
and ex vivo clinical studies.
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